100 related articles for article (PubMed ID: 23998489)
1. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S; Leoz M; Nazal L; Bruguera M; Parés A
Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
Yin Q; Li J; Xia Y; Zhang R; Wang J; Lu W; Zhou Y; Zheng Y; Abudumijiti H; Chen R; Chen K; Li S; Liu T; Wang F; Lu J; Zhou Y; Guo C
Drug Des Devel Ther; 2015; 9():5407-19. PubMed ID: 26491252
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of primary biliary cholangitis.
Laschtowitz A; de Veer RC; Van der Meer AJ; Schramm C
United European Gastroenterol J; 2020 Jul; 8(6):667-674. PubMed ID: 32299307
[TBL] [Abstract][Full Text] [Related]
4. [Primary biliary cholangitis-response criteria of first-line treatment and perspectives of second-line therapy].
Steinmann S; Schramm C
Inn Med (Heidelb); 2024 Apr; 65(4):340-346. PubMed ID: 38451288
[TBL] [Abstract][Full Text] [Related]
5. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.
Vuppalanchi R; González-Huezo MS; Payan-Olivas R; Muñoz-Espinosa LE; Shaikh F; Pio Cruz-Lopez JL; Parmar D
Clin Transl Gastroenterol; 2021 Mar; 12(4):e00327. PubMed ID: 33769355
[TBL] [Abstract][Full Text] [Related]
7. PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
Tanaka A; Corpechot C
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102358. PubMed ID: 38677506
[TBL] [Abstract][Full Text] [Related]
8. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Mayo MJ; Vierling JM; Bowlus CL; Levy C; Hirschfield GM; Neff GW; Galambos MR; Gordon SC; Borg BB; Harrison SA; Thuluvath PJ; Goel A; Shiffman ML; Swain MG; Jones DEJ; Trivedi P; Kremer AE; Aspinall RJ; Sheridan DA; Dörffel Y; Yang K; Choi YJ; McWherter CA
Aliment Pharmacol Ther; 2024 Jan; 59(2):186-200. PubMed ID: 37904314
[TBL] [Abstract][Full Text] [Related]
9. ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.
Van Hove JLK; Friederich MW; Hock DH; Stroud DA; Caruana NJ; Christians U; Schniedewind B; Michel CR; Reisdorph R; Lopez Gonzalez EDJ; Brenner C; Donovan TE; Lee JC; Chatfield KC; Larson AA; Baker PR; McCandless SE; Moore Burk MF
Mitochondrion; 2024 May; 78():101905. PubMed ID: 38797357
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate severe late onset drug-induced liver injury in primary biliary cholangitis: case report.
Jorge Nardelli M; Rodrigues Maffia L; Alves Gelape F; Grossi Lopes Cançado G; Alves Couto C
J Gastrointestin Liver Dis; 2023 Sep; 32(3):413-414. PubMed ID: 37774223
[No Abstract] [Full Text] [Related]
11. Bezafibrate Add-On Therapy Improves Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis: A Japanese Nationwide Cohort Study.
Gastroenterol Hepatol (N Y); 2021 Feb; 17(2 Suppl 3):10-11. PubMed ID: 34135715
[No Abstract] [Full Text] [Related]
12. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
14. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
15. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
16. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
Grigorian AY; Mardini HE; Corpechot C; Poupon R; Levy C
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):296-306. PubMed ID: 25882906
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
19. New therapies for primary biliary cirrhosis.
Floreani A; Franceschet I; Perini L; Cazzagon N; Gershwin ME; Bowlus CL
Clin Rev Allergy Immunol; 2015 Jun; 48(2-3):263-72. PubMed ID: 25331740
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis.
Zhang Y; Chen K; Dai W; Xia Y; Wang F; Shen M; Cheng P; Wang C; Yang J; Zhu R; Zhang H; Li J; Zheng Y; Wang J; Lu J; Zhou Y; Guo C
Hepatol Res; 2015 Jan; 45(1):48-58. PubMed ID: 24934524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
